IP Offerings Logo

Patent MarketPlace: Pharmaceutical Patents for Sale

Nutritional Compound for Gut-Brain Weight Loss (Dellinger): U.S. Patent Nos. 11,771,125 and 11,813,363

With soaring healthcare costs and an emergent chronic disease pandemic associated with obesity, there is a global need for an affordable, safe alternative to high-priced, often unreimbursed pharmaceutical solutions with limited outcomes and daunting side effects. This patent covers a nutraceutical formulation that delivers the amino acids of tryptophan to the distal end of the intestines where they convert into the appetite-appeasing neurotransmitter, serotonin. Leveraging digestive biology and vagus neuron-signaling, this innovation naturally stimulates GLP-1 hunger suppression as a safe, affordable option to prescription drugs. It is a supplement to a single, unrestricted meal each day – free of quantity, caloric, or food group requirements.

This patent family covers a safe and sustainable weight-loss regimen that consists of natural nutrients from milk and eggs – specifically formulated and engineered for precision intestinal assimilation and synaptic communication between the gut and brain. It is designed to be taken along with one meal a day for steady, consistent, no-side-effects, weight loss that is convenient and affordable for the individual. The formulation delivers precise signaling molecules to specialized cells located at the distal end of the small intestines. This signal-cell interaction sends satiety signals to the brain. In addition to weight loss, the formulation improves daily cognitive function, improves satiety hormones, enhances gastric well-being, and could potentially reduce glucose and insulin levels. Early clinical feasibility studies revealed success with results pending peer review in a leading nutrition and obesity scientific journal.

U.S. Patent Nos. 11,771,125 and 11,813,363 for a “Concentrated nutritional or supplemental compound for intestinal, gut-brain axis and neurobiological homeostasis through calibrated absorption including neurotransmitter or any equilibrating compound release to treat or mitigate disease and co-morbidities, particularly obesity and malnourishment” would be a strategic acquisition for any nutraceutical supplements supplier that is ready to introduce a 100% natural weight-loss regimen!

SIRP-Based Immunotherapy (OmniAb): International Patent Portfolio

One of the most promising cancer treatments is immunotherapy. It uses substances made by the body or in a laboratory to boost the immune system, helping the body find and destroy cancer cells. Immunotherapy can treat many different types of cancer, and it can be used alone or in combination with chemotherapy and/or other cancer treatments.

Signal regulatory proteins (SIRPs) are a family of immune receptors encompassing inhibitory, activating, nonsignaling and soluble members. CD47, a broadly expressed transmembrane glycoprotein, functions as a cellular ligand for SIRPα and γ, negatively regulating phagocytosis and antibody-directed cellular cytotoxicity (ADCC). Agents that interfere with the interaction between these SIRPs and CD47 thus activate phagocytosis and ADCC. This portfolio describes SIRPγ and SIRPβ/β2 decoy polypeptides for immunotherapy treatment of cancer, anemia, transplant rejection, asthma, allergies, auto-immune disease, and viral infection. These decoy polypeptides are variants comprising at least one amino acid modification to increase affinity of the decoy polypeptide binding to CD47.

International Patent Portfolio

This portfolio will enable any provider of cancer treatments or immunotherapy drugs to introduce a new generation of polypeptide-based signal regulatory proteins.

Molecular Disruption for Disease Transmission Mitigation (Dellinger): Patent No. 11,638,720

Our environment is laden with infectious agents, and the recent global health crisis has intensified awareness of our vulnerability to diseases that can be both pervasive and lethal. Society is constantly at risk from various infections and the rise of antimicrobial resistance (AMR). In the arms race against these evolving pathogens, scientific innovation must stay a step ahead to develop safer, more effective solutions.

This patent introduces an advanced, broad-spectrum antimicrobial solution poised to redefine infection control. The composition utilizes atomic-scale nanoparticles modified with caustic halogens that annihilate pathogens of all varieties, including viral, bacterial, and fungal species. Activated by aqueous solutions, the composition ensures deep microbial clearance without harming human tissues, setting a new precedent in infection prevention, and offering unparalleled sterility and safety. Designed for comprehensive disinfection of skin, mucosa, and internal regions, this innovation represents a leap forward in personal protection, hygiene, and risk mitigation against infectious diseases. Additional applications covered by this patent include an aqueous suspension that employs diuresis to flush the urinary tract, potentially preventing both urinary tract and sexually transmitted infection colonization. Potential clinical applications are vast and vital, including pre-surgical sterilizing scrubs, injections, phlebotomy, or IV therapy as preventive measures against nosocomial infections. This novel approach could revolutionize the prevention and treatment of various infections, giving the healthcare sector an entirely new tool in its fight against infectious diseases and AMR.

U.S. Patent No. 11,638,720 for a “Risk mitigation of infectious disease transmission from incidental and intimate contact using atomic scale molecular disruption and biocidal halo-fullerenes delivered via topical, flushing and enteral mechanisms” can be used to create the next generation of biocides to fight viral, bacterial, and fungal infections.

Longer Viability for Transplant Organs (Brady): U.S. Patent No. 11,452,288

Organ transplants save lives and restore sight to tens of thousands of Americans each year. And while there are over 100,000 Americans on waiting lists for donor organs, more and more Americans are signing up to donate their organs. A key challenge facing the organ transplant community is getting a donated organ to the recipient before the organ has deteriorated and is not usable. What an incredible tragedy it is when an organ is donated, but by the time it arrives for transplant it is no longer viable!

This patent covers an innovative approach to preserving donor organs. Hemocyanin, such as that found in the Atlantic horseshoe crab (Limulus polyphemus), will deliver oxygen directly to transplant tissues while free radical scavenging by pristine fullerenes helps maintain cellular integrity and mitigates degradation caused by oxidative stress. Horseshoe crabs have successfully evolved over millions of years by developing unique immune cells called amoebocytes. These cells have a specific and highly sensitive affinity to gram-negative bacteria and fungi – engulfing these microbes in a destructive enzymatic coagulation process. The viral-scale peptides produced by the horseshoe crab’s amoebocytes invade pathogens and disrupt replication without conferring a caustic or toxic effect on the non-pathogenic tissue. This patent creates a hemocyanin-based formulation from horseshoe crabs that is added to tissue storage and preservation media as a potent, broad-spectrum, antimicrobial supplement.

U.S. Patent No. 11,452,288 for an “Innocuous sterilant using hemocyanin and functionalized fullerenes with broad-spectrum intracellular and interstitial microbiocidal and radical scavenging effects for packaged matter, biologics and organics including liquids, gases, tissue, organs, cells, and limbs with copper mediated oxygenation for viability and preservation” will enable any biotechnology or pharmaceutical company to introduce a formulation that will dramatically improve the shelf-life of donated organs, saving or transforming even more lives.

Mini-Tablet Dispenser (Balda Medical): International Patent Portfolio

The new mini-tablets in which many drugs are being prescribed – drugs for leukemia, epilepsy, and heart disease are just three – combine the advantages of solid and liquid formulations. They are easy to swallow and provide an accurate dosage, but do not carry the risk of over- or under-dosage that liquids present.

What is needed is a dispenser specifically for this new generation of mini-tablets, and that what this international patent portfolio creates. The dispenser covered by this portfolio stores and dispenses one mini-tablet at a time without breaking or crushing tables in the process. It has an activation lock to prevent misuse. Its rotational design insures controlled dosage of the mini-tablets it holds and it provides visual control of the dosage. The unit is easily locked to secure the tablets, and it is compact enough to be easily stored in a pocketbook.

Patent Portfolio

Any manufacturer of pharmaceutical packaging could use this portfolio to introduce the first packaging product specifically designed to meet the needs of those with a prescription drug in mini-tablet form.

Opioid Medications to Prevent Overdose or Death During Treatment (Presti): International Patent Portfolio

The U.S. Department of Health and Human Services reports that deaths from drug overdose have risen steadily over the past two decades to the point that they have become the leading cause of deaths from injury in the United States. Deaths from opioid overdoses have surpassed automobile accident fatalities, the leading cause of injury deaths in U.S. for the last century. Worse yet, many opioid addicts enter treatment, but then overdose during treatment when they self-medicate with alcohol. According to the Centers for Disease Control (CDC), nearly one quarter of fatal prescription opioid overdoses in the U.S. are associated with patients making the all-too-common mistake of drinking alcohol while medicated. When combined, alcohol and opioids interact in the brain increasing the risk of respiratory depression and death.

This portfolio aims to prevent opioid deaths head-on by solving this critical, but previously unaddressed, dimension of the opioid crisis. It includes several combination drug therapies that reduce the likelihood of an alcohol-mediated opioid overdose or death during maintenance therapy for management of pain or opioid use disorder. It covers a single composition comprising an effective amount of one or more opioid medications and an effective amount of one of 20 aldehyde dehydrogenase inhibitors or one of 65 opioid medications. It also includes a combination medication comprised of an effective amount of one or more opioid medications, an effective amount of one or more aldehyde dehydrogenase inhibitors, and a pharmaceutical carrier.

This extensive portfolio additionally includes a combination medication that is comprised of one or more opioid medications from 1 to 200 mg, a disulfiram or pharmaceutically acceptable salt from 50 to 250 mg, and a carrier. Specifically directed at reducing an alcohol-mediated opioid overdose or death during maintenance therapy for pain management, the portfolio covers a single composition comprised of one or more opioid pain medications from 1 to 200 mg and a disulfiram or pharmaceutically acceptable salt from 50 to 250 mg that prevents alcohol consumption in the patient. There are additional formulations in three pending patent applications.

Patent Portfolio

This portfolio offers a pharmaceutical company the opportunity to introduce the next generation of opioid treatments – a regimen that specifically addresses opioid patients that face severe pains issues during treatment at high risk of drinking alcohol during their treatment for pain or addiction.

Nutraceutical Treatment for Gout (Truscott): U.S. and European Patents

Gout is a form of inflammatory arthritis that is caused by excess uric acid in the blood that crystallizes in joints and other tissues. Among those with gout, 90% have kidneys that don’t adequately remove uric acid from their urine, while 10% have high uric acid levels because their bodies produce too much uric acid. Between eight and nine million Americans suffer from gout – and millions more in Europe. Gout can be very painful – even disabling. Most treatments for gout address the pain and inflammation caused by the condition, not the root cause of the disease!

This portfolio covers a safe and effective treatment for gout that is composed of natural ingredients – celery seed extract, cherry extract, and elemental lithium in a lithium salt. The components work synergistically to inhibit painful uric acid crystals by three different modes of action: Inhibition of uric acid formation (celery seed extract), increase in uric acid elimination from the body (cherry extract), and interference with crystallization itself (lithium). Since the ingredients are all-natural, a gout treatment based on these patents can be sold over-the-counter without a prescription.

U.S. Patent No. 9,149,500 and European Patent 2303302 for a “Method and process for relieving or preventing symptoms” would enable any pharmaceutical supplier or natural remedy manufacturer to bring a treatment for gout to the market very quickly!

Urinary Tract Infection Prevention and Treatment (Biomedicals Science Sweden): International Patent Portfolio

In the science fiction thriller The Andromeda Strain, scientists attempting to stop an infection from outer space discover that the disease can only survive in a narrow pH range. The same is true of many infections here on earth including bacteria that can make its way up the urinary tract to infect the bladder (causing cystitis) or kidneys (causing pyelonephritis). Controlling the pH level in the patient’s urinary tract can prevent bacteria from becoming an infection.

This portfolio covers alternating administrations of a pH-increasing agent with the administration of a pH-decreasing agent to the patient via a mannose solution. The pH-increasing agent is administered at a dosage of about 0.1 to 20 grams per day, while the pH-decreasing agent is administered to at a dosage of about 0.1 to 20 grams per day, and the mannose or other solution is administered to at a dosage of about 0.1 to 50 grams per day.

Urinary Tract Infection Portfolio

This portfolio can be developed into a product that is sold over-the-counter in pharmacies or is used in physician’s offices as a pre-treatment prior to prescribing antibiotics. It can also be used in hospitals after surgery to lower the risk of infection and as a product for catheter patients, significantly lowering the use of antibiotics among this high-risk infection group. This portfolio will enable any drug manufacturer to introduce a product that totally prevents, or very quickly and effectively treats, a urinary tract infection without the use of antibiotics and their resulting side effects.

Treatment for Afflictions of the Central Nervous System (Numazawa): U.S. and Japanese Patents

It is not uncommon for a drug that was originally developed to treat one disease or condition to be found to also treat another disease or condition. For example, minoxidil, the active ingredient in Rogaine® (the popular treatment for male pattern baldness) was originally developed to treat high blood pressure! This is known as “drug repositioning.”

This patent portfolio addresses new uses for two existing drugs – Methocarbamol and Chlorphenesin Carbamate – for the treatment of central nervous system afflictions such as mood disorders, mental disorders, chronic fatigue syndrome, depression, and Alzheimer’s. The inventor has three published medical research papers documenting the effectiveness of this patented drug combination.

This portfolio includes U.S. Patent No. 11,364,218 for a “Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome” and Japanese Patent 6216913 for a “Pharmaceutical composition.” Since the two drugs on which the patents are based are already FDA-approved, the acquirer of the patents should be able to go to market with a drug for the treatment of depression and Alzheimer’s fairly quickly.

Rogaine is a registered trademark of Johnson & Johnson Services, Inc.

Production of Very Pure HMR and NTG Lignans (Montisera): International Patent Portfolio

Lignans are a little-known group of low molecular weight polyphenols that are derived from trees and other ligneous plants. HMR (hydroxymatairesinol) lignans are a powerful antioxidant and immune system booster that is used in by humans as well as dogs and cats. It is also an enterolactone precursor with anticancer activities. Testing has shown that HMR lignans decrease the volume of induced tumors and stabilize established tumors – and prevent the development of new tumors – in rats. HMR lignans and NTG (nortrachelogenin) lignans are also key ingredients in natural cosmetics that offer anti-aging properties. Research has shown promise for NTG lignans in treating prostate cancer.

The challenge is refining lignans through the fractionation of knotwood extract. This portfolio covers a process that in which hydrophilic extract is extracted with a lipophilic solvent that removes lipophilic impurities. The portfolio also covers the use of liquid-to-liquid extraction for the purification of hydrophilic knotwood extract. The patented process provides a purified extract that contains more than 90 % lignans, flavonoids, and stilbenes, and less than 10 % in impurities.

Patent Portfolio